Global Bispecific Antibody Market Size By Drug Type (Blinatumomab, Catumaxomab), By Indication (Cancer, Infectious Disease), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Geographic Scope And Forecast

Bispecific Antibody Market Size And Forecast

Bispecific Antibody Market size is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e., 2022 to 2030.

The rise in special designation from regulatory authorities is projected to be a major factor driving the growth of the bispecific antibody market during the forecast period. Furthermore, the continuous clinical trials done by various pharmaceutical industries are expected to drive the expansion of the bispecific antibody market. The Global Bispecific Antibody Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Bispecific Antibody Market Definition

A bispecific antibody (BsAb) is an artificial protein made up of fragments of two distinct monoclonal antibodies that can bind to two different types of antigens. Quadromas, chemical heteroconjugates, bispecific antibodies with particular heterodimerization domains, and bispecific antibodies of minimum size are all examples of bispecific antibody forms. Bispecific antibodies are largely used in cancer therapy and are developing as a revolutionary technique for two targeting methods inside a single molecule for cancer treatment.

Bispecific antibodies enhance and assure the following properties in a cancer-targeted agentincreased binding capacity, selectivity, and effectiveness. It has been discovered that bispecific antibodies had superior efficacy for cancer treatment when compared to combination therapy with the other two antibodies. The backbone of the fast growth of bispecific antibody formats has been recognized as recombinant DNA technology.

Bispecific antibodies are becoming the most popular and effective technique for treating cancers such as breast, lung, prostate, and colon cancer. With the increasing frequency of several forms of cancer (lung cancer, breast cancer, and cervical cancer), the global market for bispecific antibody therapy is rapidly expanding. Furthermore, according to the California Journal of Clinical Cancer, one out of every six males in the United States has had a prostate cancer diagnostic test at some time in their lives (CJCC). However, the technological complexity of the bispecific antibody treatment technique (detection) would impede worldwide market demand for bispecific antibody therapy over the research period.

Global Bispecific Antibody Market Overview

One of the primary reasons driving the growth of the bispecific antibody market is the increasing need for bispecific antibodies for the treatment of infectious illnesses, cancer tumors, bacterial infections, and cancer diagnostics. As the number of cancer patients and infectious illness patients grows, so does the need to cure them. Several bispecific antibody cytokines, for example, have been discovered as key mediators in the development of inflammatory and autoimmune illnesses, according to the Journal of Hematology & Oncology. As a result, inhibiting these cytokines offers therapeutic potential in the treatment of inflammatory and infectious disorders. TNF-inhibition has been shown to be effective in the treatment of psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, juvenile arthritis, and a range of other illnesses. According to the WHO, infectious illnesses cause 9.5 million deaths each year, posing a significant socioeconomic cost to society. Global healthcare systems utilize surveillance strategies to restrict the spread of infectious illnesses, which rely on early detection. In addition, 18.1 million people were diagnosed with cancer globally in 2018, with 9.6 million dying as a result.

Furthermore, the increasing number of Covid-19 instances is contributing to market development. Bispecific antibodies can be utilized to treat Covid-19 patients in order to improve antibody potential. According to the Taylor and Francis mAbs Journal, a substantial number of SARS-CoV-2 neutralizing bispecific antibodies have been discovered, with the bulk of them directly inhibiting the viral Spike receptor-binding domain (RBD) from binding to angiotensin-converting enzyme (ACE2). Fabs are phage display antigen-binding fragments that bind RBD but do not inhibit ACE2 or kill the virus. When these non-neutralizing Fabs were assembled into bispecific VH/Fab immunoglobulin with a neutralizing VH domain and compared to the mono-specific bivalent VH-Fc alone or the cocktail of the VH-Fc and Immunoglobulin, a 25-fold improvement in neutralizing SARS-CoV-2 was seen. Creating a bispecific antibody with both neutralizing and non-neutralizing epitopes on Spike-RBD is a potential and efficient engineering strategy for increasing the effectiveness of SARS-CoV-2 antibodies.

However, the high cost of pharmaceuticals and R&D expenditure may limit the worldwide bispecific antibody market’s growth. Despite this, increased research and development initiatives in this industry may generate new prospects for the market’s future growth.

Global Bispecific Antibody MarketSegmentation Analysis

The Global Bispecific Antibody Market is segmented based on Drug Type, Indication, Distribution Channel, and Geography.

Bispecific Antibody Market, By Drug Type

• Blinatumomab• Catumaxomab• Duligotumab

Based on Drug Type, the market is further segmented into Blinatumomab, Catumaxomab, and Duligotumab. The medicine type blinatumomab generates the most revenue in the bispecific antibody market. Blinatumomab is used to treat specific kinds of acute lymphocytic leukemia in adults and children that have not improved or have returned despite therapy with other drugs.

Bispecific Antibody Market, By Indication

• Cancer• Infectious Disease• Inflammatory and Autoimmune Disorders• CNS Disorders

Based on Indication, the market is segmented into Cancer, Infectious Disease, Inflammatory and Autoimmune Disorders, CNS Disorders. Cancer is expected to be the greatest revenue-generating segment because of its enormous patient population. Cancer immunotherapy is the most extensively researched use of bispecific antibodies. BsAb has a broader range of uses, including lung, breast, and colon cancer. A bispecific antibody attaches to a cytotoxic cell and a tumor cell at the same time and eliminates both. Bispecific antibodies, a technologically sophisticated solution for two targeting techniques inside the same molecule, are emerging.

Bispecific Antibody Market, By Distribution Channel

• Hospital Pharmacies• Retail Pharmacies• Drug stores• Online Pharmacies

Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies. Hospital pharmacies segment is dominating the market followed by retail pharmacies. Online pharmacies, on the other hand, are likely to rise at a rapid pace over the forecast period due to improvements in digital technologies in the bispecific antibody market.

Bispecific Antibody Market, By Geography

• North America• Europe• Asia Pacific• Rest of the World

Based on regional analysis, the Global Bispecific Antibody Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. As significant market participants are situated in these areas, North America and Europe were discovered to have the largest bispecific antibodies treatment market. Furthermore, it has been observed that the highest number of cancer diagnostic cases (lung cancer, prostate cancer, breast cancer, and cervical cancer) are documented in North America and Europe each year. Furthermore, favorable federal government efforts would be accounted for in the market expansion of bispecific antibody therapy in the North American and European areas. Similarly, due to a lack of good healthcare facilities in several Asian nations, Asia-Pacific is regarded as an undeveloped market in bispecific antibody therapy. The emergence of unexplored prospects as a result of considerable investment in healthcare infrastructure will drive Asian market growth (healthcare cost, healthcare facility, and healthcare budget).

Key Players

The “Global Bispecific Antibody Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are Merck, Amgen, Johnson & Johnson, AbbVie Inc., Bayer AG, Pfizer Inc., Bristol-Myers Squibb, Sonafi S.A., OncoMed Pharmaceuticals, Portola Pharmaceuticals, Ganymed Pharmaceuticals amongst others are a few major companies operating in the Bispecific Antibody Market. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In January 2019, the Chinese Academy of Medical Sciences and Peking Union Medical College collaborated to create a novel bispecific aptamer that boosts immune cytotoxicity against MUC1-positive tumor cells.

• In September 2018, researchers from China Pharmaceutical University created and generated a completely human, bispecific, single-chain diabody that can bind to VEGF165 and programmed death-1 in Pichia pastoris.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any  please connect with our sales team, who will ensure that your requirements are met.